HomeCompareMXDHF vs PLD

MXDHF vs PLD: Dividend Comparison 2026

MXDHF yields 800.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MXDHF wins by $2773890.56M in total portfolio value
10 years
MXDHF
MXDHF
● Live price
800.00%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2773896.46M
Annual income
$2,226,430,694,490.38
Full MXDHF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — MXDHF vs PLD

📍 MXDHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMXDHFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MXDHF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MXDHF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MXDHF
Annual income on $10K today (after 15% tax)
$68,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,892,466,090,316.82/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, MXDHF beats the other by $1,892,462,052,200.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MXDHF + PLD for your $10,000?

MXDHF: 50%PLD: 50%
100% PLD50/50100% MXDHF
Portfolio after 10yr
$1386951.19M
Annual income
$1,113,217,722,607.78/yr
Blended yield
80.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MXDHF
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-3.4
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MXDHF buys
0
PLD buys
0
No recent congressional trades found for MXDHF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMXDHFPLD
Forward yield800.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$2773896.46M$5.91M
Annual income after 10y$2,226,430,694,490.38$4,750,725.19
Total dividends collected$2730603.49M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: MXDHF vs PLD ($10,000, DRIP)

YearMXDHF PortfolioMXDHF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$90,700$80,000.00$11,241$540.96+$79.5KMXDHF
2$775,180$678,130.84$13,019$991.13+$762.2KMXDHF
3$6,246,019$5,416,576.76$15,801$1,870.97+$6.23MMXDHF
4$47,472,138$40,788,897.61$20,609$3,701.21+$47.45MMXDHF
5$340,525,323$289,730,135.14$29,919$7,867.97+$340.50MMXDHF
6$2,306,680,888$1,942,318,792.24$50,631$18,617.74+$2306.63MMXDHF
7$14,764,459,529$12,296,310,979.28$105,528$51,352.20+$14764.35MMXDHF
8$89,354,478,583$73,556,506,887.09$287,364$174,449.42+$89354.19MMXDHF
9$511,650,252,638$416,040,960,553.41$1,081,760$774,280.77+$511649.17MMXDHF
10$2,773,896,464,813$2,226,430,694,490.38$5,908,209$4,750,725.19+$2773890.56MMXDHF

MXDHF vs PLD: Complete Analysis 2026

MXDHFStock

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Full MXDHF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MXDHF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MXDHF vs SCHDMXDHF vs JEPIMXDHF vs OMXDHF vs KOMXDHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.